Press Releases

MGEN $6.39 $ - 0.10 (1.54%)

Press Releases

Search Press Releases
  
Subscribe for Email Alerts
4/19/2018
7:00 AM ET
Press Release

miRagen Therapeutics to Present New Preclinical Data at the Wound Healing Society and the Association for Research in Vision and Ophthalmology Annual Meetings

4/19/2018

BOULDER, Colo., April 19, 2018 (GLOBE NEWSWIRE) -- miRagen Therapeutics, Inc. (NASDAQ:MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted thera...

 Continue Reading
3/27/2018
7:00 AM ET
Press Release

miRagen Announces Initiation of Phase 1 Clinical Trial of MRG-110

3/27/2018

BOULDER, Colo., March 27, 2018 (GLOBE NEWSWIRE) -- miRagen Therapeutics, Inc. (NASDAQ:MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted thera...

 Continue Reading
3/14/2018
4:05 PM ET
Earnings Release

miRagen Therapeutics Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Corporate Update

3/14/2018

Data from Phase 1 clinical trial supports advancing cobomarsen, or MRG-106, into a Phase 2 potentially registrational clinical trial for CTCL (the SOLAR trial)Completed Phase 1 clinical trial of MRG-2...

 Continue Reading
3/7/2018
7:00 AM ET
Press Release

miRagen Therapeutics to Report Fourth Quarter and Full Year 2017 Financial Results and Host Conference Call on March 14, 2018

3/7/2018

BOULDER, Colo., March 07, 2018 (GLOBE NEWSWIRE) -- miRagen Therapeutics, Inc. (NASDAQ:MGEN) a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therap...

 Continue Reading
3/5/2018
7:00 AM ET
Press Release

miRagen Therapeutics to Participate in Upcoming Investor Conferences

3/5/2018

BOULDER, Colo., March 05, 2018 (GLOBE NEWSWIRE) -- miRagen Therapeutics, Inc. (NASDAQ:MGEN) a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therap...

 Continue Reading
Displaying 1 to 5 (of 45 releases)